Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
eptinezumab-jjmr
|
| gptkbp:administrativeDivision |
once every three months
healthcare_professional_administration |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
Vyepti
|
| gptkbp:chemicalFormula |
IgG1 monoclonal antibody
|
| gptkbp:clinicalTrials |
gptkb:PROMISE-2
Phase 3 EVOLVE-1 EVOLVE-2 chronic migraine episodic migraine recommended for migraine prevention PROMISE-1 REGAIN |
| gptkbp:contraindication |
hypersensitivity to eptinezumab
|
| gptkbp:developedBy |
gptkb:Alder_BioPharmaceuticals
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
none known
long half-life CGRP inhibition CGRP inhibitors |
| gptkbp:formulation |
sterile solution
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
treatment adherence
injection technique side effects awareness |
| https://www.w3.org/2000/01/rdf-schema#label |
Eptinezumab
|
| gptkbp:impact |
ongoing
improved quality of life reduce frequency of migraines |
| gptkbp:is_monitored_by |
adverse effects
migraine frequency |
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2020
|
| gptkbp:mandates |
migraine prevention
|
| gptkbp:market |
2020
|
| gptkbp:marketedAs |
Vyepti
|
| gptkbp:offers |
high
|
| gptkbp:patentAssignee |
gptkb:Alder_BioPharmaceuticals
|
| gptkbp:researchAreas |
neurology
pain management |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
nausea injection site reactions upper respiratory tract infection |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
CGRP (Calcitonin Gene-Related Peptide)
|
| gptkbp:triggerType |
CGRP receptor antagonist
|
| gptkbp:usedFor |
preventing migraine
|